首页 > 最新文献

Expert review of medical devices最新文献

英文 中文
Swiftsure complete care system in intubated adults: a feasibility study. Swiftsure成人插管完整护理系统的可行性研究。
IF 2.7 Pub Date : 2025-11-01 Epub Date: 2025-10-24 DOI: 10.1080/17434440.2025.2576586
Victor F A Almeida, Aline Reuter Pimenta, Valentina Lara-Erazo, Deeven Karki, Fabio Rodriguez-Patarroyo, Julia Semeia, Hanna Duncan, Nikolina Filipovic, Derek Meyer, Marcelo Gama de Abreu

Background: Mechanically ventilated patients are at risk of respiratory complications, which may be reduced by proper oral care. The oral cleaning device (Swishkit, Swiftsure, Vancouver, Canada) was developed to facilitate cleansing, moisturization, and debris removal in intubated patients. We aimed to evaluate the feasibility and usability of this device in adult intensive care patients.

Methods: We conducted a prospective, single-center study at the Cleveland Clinic. Adult patients recovering from cardiac surgery and expected to remain intubated ≥2 hours were included. Feasibility was defined as successful completion of the procedure by nursing staff in addition to standard care. Usability was assessed with the Device Use Questionnaire (DUQ), scored on a 5-point scale (1 = easiest, 2.5 = neutral, 5 = difficult).

Results: Twenty-two patients were enrolled. The procedure was completed in 21/22 (95.5%). One attempt failed due to jaw clenching that prevented device placement, but this patient was included in the analysis. DUQ scores ranged from 1.3 to 2.3, reflecting easy to neutral usability. More than 85% of responses to usability questions were positive, and no residual saline was observed in the subglottic region.

Conclusion: Oral cavity cleansing with the oral cleaning device proved feasible and clinically usable in intubated patients recovering from cardiac surgery.

Trial registration: ClinicalTrials.gov Identifier: NCT05578599.

方法:我们在克利夫兰诊所进行了一项前瞻性单中心研究。包括心脏手术后恢复并预计插管≥2小时的成年患者。可行性定义为除标准护理外,护理人员成功完成手术。可用性通过设备使用问卷(DUQ)进行评估,得分为5分(1 =最简单,2.5 =中性,5 =困难)。结果:22例患者入组。手术于2011 /22完成(95.5%)。一次尝试失败,由于咬紧牙关,阻止装置放置,但该患者被纳入分析。DUQ得分在1.3到2.3之间,反映了易用性到中性的易用性。超过85%的可用性问题的回答是积极的,并且在声门下区域没有观察到残留的生理盐水。结论:口腔清洁装置在心脏手术后插管患者口腔清洁中是可行的,可用于临床。试验注册:ClinicalTrials.gov标识符:NCT05578599。
{"title":"Swiftsure complete care system in intubated adults: a feasibility study.","authors":"Victor F A Almeida, Aline Reuter Pimenta, Valentina Lara-Erazo, Deeven Karki, Fabio Rodriguez-Patarroyo, Julia Semeia, Hanna Duncan, Nikolina Filipovic, Derek Meyer, Marcelo Gama de Abreu","doi":"10.1080/17434440.2025.2576586","DOIUrl":"10.1080/17434440.2025.2576586","url":null,"abstract":"<p><strong>Background: </strong>Mechanically ventilated patients are at risk of respiratory complications, which may be reduced by proper oral care. The oral cleaning device (Swishkit, Swiftsure, Vancouver, Canada) was developed to facilitate cleansing, moisturization, and debris removal in intubated patients. We aimed to evaluate the feasibility and usability of this device in adult intensive care patients.</p><p><strong>Methods: </strong>We conducted a prospective, single-center study at the Cleveland Clinic. Adult patients recovering from cardiac surgery and expected to remain intubated ≥2 hours were included. Feasibility was defined as successful completion of the procedure by nursing staff in addition to standard care. Usability was assessed with the Device Use Questionnaire (DUQ), scored on a 5-point scale (1 = easiest, 2.5 = neutral, 5 = difficult).</p><p><strong>Results: </strong>Twenty-two patients were enrolled. The procedure was completed in 21/22 (95.5%). One attempt failed due to jaw clenching that prevented device placement, but this patient was included in the analysis. DUQ scores ranged from 1.3 to 2.3, reflecting easy to neutral usability. More than 85% of responses to usability questions were positive, and no residual saline was observed in the subglottic region.</p><p><strong>Conclusion: </strong>Oral cavity cleansing with the oral cleaning device proved feasible and clinically usable in intubated patients recovering from cardiac surgery.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT05578599.</p>","PeriodicalId":94006,"journal":{"name":"Expert review of medical devices","volume":" ","pages":"1265-1270"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145350552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expert-involved continuous renal replacement therapy device development: addressing user needs through human factors engineering. 专家参与的持续肾替代治疗设备开发:通过人因工程解决用户需求。
IF 2.7 Pub Date : 2025-11-01 Epub Date: 2025-09-23 DOI: 10.1080/17434440.2025.2561925
J Choi, C H Park, H Lim, S Kwon, T W Koo, Y Ryu, S Cho, S G Kim, S Lee, H Huh, D K Kim, S Lee, J C Lee

Background: Continuous renal replacement therapy (CRRT) devices are essential for critically ill patients but present significant usability challenges that create use-related risks affecting patient safety. This study applied expert-involved usability engineering to develop a user-centered CRRT device.

Methods: A three-phase study engaged 233 experts: Phase 1 assessed user needs through an online survey (n = 204) identifying use-related risks. Phase 2 developed and iteratively refined a CRRT prototype through expert review (n = 8) and heuristic evaluation (n = 5). Phase 3 validated the final prototype with ICU nurses (n = 16) through task performance in simulated ICU environments. Main outcomes included user satisfaction scores and use error observations.

Results: Phase 1 identified user needs and use-related risks, which were translated into user interface requirements. The initial prototype was developed and refined after iterative usability tests. The final prototype demonstrated high satisfaction scores: Overall User Experience 4.29 ± 0.53, Ease of Use 4.23 ± 0.50, and Comparative Assessment 3.56 ± 0.72. The validation test confirmed effective mitigation of use-related risks. Eight use errors and 48 use difficulties were identified for further refinement.

Conclusions: Systematic expert involvement in usability engineering successfully developed a CRRT device that effectively mitigated use-related risks while achieving high user satisfaction, demonstrating the value of expert integration in medical device development.

背景:持续肾替代治疗(CRRT)设备设备对危重患者至关重要,但存在显著的可用性挑战,产生影响患者安全的使用相关风险。本研究运用专家参与的可用性工程,开发以用户为中心的CRRT装置。方法:一项由233名专家参与的三阶段研究:第一阶段通过在线调查(n = 204)评估用户需求,确定与使用相关的风险。第二阶段通过专家评审(n = 8)和启发式评估(n = 5)开发并迭代改进了CRRT原型。第三阶段通过ICU护士(n = 16)在模拟ICU环境中的任务表现对最终原型进行验证。主要结果包括用户满意度评分和使用错误观察。结果:阶段1确定了用户需求和与使用相关的风险,并将其转化为用户界面需求。最初的原型是在反复的可用性测试之后开发和完善的。最终原型的满意度得分很高:整体用户体验4.29±0.53,易用性4.23±0.50,比较评估3.56±0.72。验证测试确认有效减轻了与使用有关的风险。确定了8个使用错误和48个使用难点,以进一步完善。结论:系统的专家参与可用性工程,成功开发了CRRT设备,有效降低了使用相关风险,同时获得了较高的用户满意度,展示了专家集成在医疗器械开发中的价值。
{"title":"Expert-involved continuous renal replacement therapy device development: addressing user needs through human factors engineering.","authors":"J Choi, C H Park, H Lim, S Kwon, T W Koo, Y Ryu, S Cho, S G Kim, S Lee, H Huh, D K Kim, S Lee, J C Lee","doi":"10.1080/17434440.2025.2561925","DOIUrl":"10.1080/17434440.2025.2561925","url":null,"abstract":"<p><strong>Background: </strong>Continuous renal replacement therapy (CRRT) devices are essential for critically ill patients but present significant usability challenges that create use-related risks affecting patient safety. This study applied expert-involved usability engineering to develop a user-centered CRRT device.</p><p><strong>Methods: </strong>A three-phase study engaged 233 experts: Phase 1 assessed user needs through an online survey (<i>n</i> = 204) identifying use-related risks. Phase 2 developed and iteratively refined a CRRT prototype through expert review (<i>n</i> = 8) and heuristic evaluation (<i>n</i> = 5). Phase 3 validated the final prototype with ICU nurses (<i>n</i> = 16) through task performance in simulated ICU environments. Main outcomes included user satisfaction scores and use error observations.</p><p><strong>Results: </strong>Phase 1 identified user needs and use-related risks, which were translated into user interface requirements. The initial prototype was developed and refined after iterative usability tests. The final prototype demonstrated high satisfaction scores: Overall User Experience 4.29 ± 0.53, Ease of Use 4.23 ± 0.50, and Comparative Assessment 3.56 ± 0.72. The validation test confirmed effective mitigation of use-related risks. Eight use errors and 48 use difficulties were identified for further refinement.</p><p><strong>Conclusions: </strong>Systematic expert involvement in usability engineering successfully developed a CRRT device that effectively mitigated use-related risks while achieving high user satisfaction, demonstrating the value of expert integration in medical device development.</p>","PeriodicalId":94006,"journal":{"name":"Expert review of medical devices","volume":" ","pages":"1243-1256"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145071220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sutureless versus transcatheter aortic valve replacement: propensity matched analysis. 无缝合与经导管主动脉瓣置换术:倾向匹配分析。
IF 2.7 Pub Date : 2025-11-01 Epub Date: 2025-09-22 DOI: 10.1080/17434440.2025.2563619
Marie Lamberigts, Bert Sarrazin, Delphine Szecel, Filip Rega, Peter Verbrugghe, Christophe Dubois, Bart Meuris

Background: The goal of this study is to perform a propensity score matched analysis of sutureless AVR and TAVR to compare patient characteristics and postoperative outcomes including hemodynamic performance.

Methods: Patients treated with either sutureless aortic valve replacement (SU-AVR) using PercevalTM or transcatheter aortic valve replacement between October 2017 and June 2022 were included. Propensity score matching (PSM) was used to limit the bias in a non-randomized study.

Results: After PSM, 118 pairs of patients were obtained. The in-hospital mortality rate was 0% in SU-AVR and 4.2% in TAVR (p = 0.063). Postoperative complication rates including disabling stroke (0% vs 2.5%, p = 0.250), new need for dialysis (1.7% vs 0%, p = 0.500), and permanent pacemaker implantation at 30 days (5.9% vs 10.2%, p = 0.332) showed no statistical difference. At discharge, TAVR showed significantly lower peak and mean gradients, while paravalvular leakage higher than 1/4 was significantly higher in TAVR (11% vs 0%, p < 0.001).

Conclusions: TAVR offers significantly better transprosthetic gradients, shorter ICU and hospital stays, and less need for postoperative dialysis. Surgery using a sutureless valve showed less paravalvular leakage.

背景:本研究的目的是对无缝线AVR和TAVR进行倾向评分匹配分析,以比较患者特征和术后结果,包括血流动力学表现。方法:纳入2017年10月至2022年6月期间使用PercevalTM进行无缝线主动脉瓣置换术(SU-AVR)或经导管主动脉瓣置换术的患者。倾向评分匹配(PSM)用于限制非随机研究的偏倚。结果:经PSM治疗,获得118对患者。SU-AVR组住院死亡率为0%,TAVR组为4.2% (p = 0.063)。术后并发症发生率包括致残性卒中(0% vs 2.5%, p = 0.250)、新需要透析(1.7% vs 0%, p = 0.500)和30天永久性起搏器植入(5.9% vs 10.2%, p = 0.332),差异无统计学意义。出院时,TAVR的峰值和平均梯度明显降低,而高于1/4的瓣旁漏明显高于TAVR (11% vs 0%, p)。结论:TAVR具有明显更好的经假体梯度,缩短ICU和住院时间,减少术后透析需求。无缝合线瓣膜手术显示瓣旁渗漏较少。
{"title":"Sutureless versus transcatheter aortic valve replacement: propensity matched analysis.","authors":"Marie Lamberigts, Bert Sarrazin, Delphine Szecel, Filip Rega, Peter Verbrugghe, Christophe Dubois, Bart Meuris","doi":"10.1080/17434440.2025.2563619","DOIUrl":"10.1080/17434440.2025.2563619","url":null,"abstract":"<p><strong>Background: </strong>The goal of this study is to perform a propensity score matched analysis of sutureless AVR and TAVR to compare patient characteristics and postoperative outcomes including hemodynamic performance.</p><p><strong>Methods: </strong>Patients treated with either sutureless aortic valve replacement (SU-AVR) using Perceval<sup>TM</sup> or transcatheter aortic valve replacement between October 2017 and June 2022 were included. Propensity score matching (PSM) was used to limit the bias in a non-randomized study.</p><p><strong>Results: </strong>After PSM, 118 pairs of patients were obtained. The in-hospital mortality rate was 0% in SU-AVR and 4.2% in TAVR (<i>p</i> = 0.063). Postoperative complication rates including disabling stroke (0% vs 2.5%, <i>p</i> = 0.250), new need for dialysis (1.7% vs 0%, <i>p</i> = 0.500), and permanent pacemaker implantation at 30 days (5.9% vs 10.2%, <i>p</i> = 0.332) showed no statistical difference. At discharge, TAVR showed significantly lower peak and mean gradients, while paravalvular leakage higher than 1/4 was significantly higher in TAVR (11% vs 0%, <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>TAVR offers significantly better transprosthetic gradients, shorter ICU and hospital stays, and less need for postoperative dialysis. Surgery using a sutureless valve showed less paravalvular leakage.</p>","PeriodicalId":94006,"journal":{"name":"Expert review of medical devices","volume":" ","pages":"1271-1278"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Teleophthalmology-enabled devices: bridging the gap in rural eye care. 远程眼科设备:弥合农村眼科护理的差距。
IF 2.7 Pub Date : 2025-11-01 Epub Date: 2025-10-15 DOI: 10.1080/17434440.2025.2566741
Bharat Gurnani, Kirandeep Kaur

Introduction: Rural populations bear a disproportionate burden of preventable vision loss due to scant ophthalmic resources, long travel distances, and delayed diagnoses of vision-threatening conditions such as diabetic retinopathy, glaucoma, and age-related macular degeneration. Teleophthalmology, leveraging portable imaging devices, data connectivity, and remote interpretation, offers a critical solution by bringing diagnostic capabilities to underserved communities and enabling earlier intervention before irreversible vision loss occurs.

Areas covered: This report reviews the evolution and performance of handheld fundus cameras and smartphone-based adapters for ophthalmic imaging, as well as portable and home-based OCT systems for high-resolution structural assessment. We summarize key studies that validate device accuracy and examine artificial intelligence algorithms that autonomously grade retinal images with regulatory clearance. We also discuss implementation challenges, including infrastructure gaps, image-quality limitations, cost-utility data, and outline strategies such as hybrid AI-expert workflows, federated learning, and integration of tele-eye care into existing public health programs.

Expert opinion: Teleophthalmology devices have matured into reliable tools that can democratize eye care. Their success depends on robust digital infrastructure, rigorous device and algorithm validation, and sustainable financing models. Investment in local training, community engagement, and interoperable referral networks is crucial for translating technological advances into meaningful reductions in rural vision impairment.

由于缺乏眼科资源、路途遥远以及糖尿病视网膜病变、青光眼和老年性黄斑变性等视力威胁疾病的诊断延迟,农村人口承受着不成比例的可预防的视力丧失负担。远程眼科利用便携式成像设备、数据连接和远程口译,为服务不足的社区提供了诊断能力,并在发生不可逆转的视力丧失之前进行早期干预,从而提供了一种关键的解决方案。涵盖领域:本报告回顾了用于眼科成像的手持式眼底相机和基于智能手机的适配器的发展和性能,以及用于高分辨率结构评估的便携式和家用OCT系统。我们总结了验证设备准确性的关键研究,并研究了具有监管许可的视网膜图像自主分级的人工智能算法。我们还讨论了实施方面的挑战,包括基础设施差距、图像质量限制、成本效用数据和概述策略,如混合人工智能-专家工作流程、联邦学习以及将远程眼保健集成到现有的公共卫生计划中。专家意见:远程眼科设备已经成熟为可靠的工具,可以民主化的眼睛护理。它们的成功取决于强大的数字基础设施、严格的设备和算法验证以及可持续的融资模式。投资于地方培训、社区参与和可互操作的转诊网络,对于将技术进步转化为有意义地减少农村视力障碍至关重要。
{"title":"Teleophthalmology-enabled devices: bridging the gap in rural eye care.","authors":"Bharat Gurnani, Kirandeep Kaur","doi":"10.1080/17434440.2025.2566741","DOIUrl":"10.1080/17434440.2025.2566741","url":null,"abstract":"<p><strong>Introduction: </strong>Rural populations bear a disproportionate burden of preventable vision loss due to scant ophthalmic resources, long travel distances, and delayed diagnoses of vision-threatening conditions such as diabetic retinopathy, glaucoma, and age-related macular degeneration. Teleophthalmology, leveraging portable imaging devices, data connectivity, and remote interpretation, offers a critical solution by bringing diagnostic capabilities to underserved communities and enabling earlier intervention before irreversible vision loss occurs.</p><p><strong>Areas covered: </strong>This report reviews the evolution and performance of handheld fundus cameras and smartphone-based adapters for ophthalmic imaging, as well as portable and home-based OCT systems for high-resolution structural assessment. We summarize key studies that validate device accuracy and examine artificial intelligence algorithms that autonomously grade retinal images with regulatory clearance. We also discuss implementation challenges, including infrastructure gaps, image-quality limitations, cost-utility data, and outline strategies such as hybrid AI-expert workflows, federated learning, and integration of tele-eye care into existing public health programs.</p><p><strong>Expert opinion: </strong>Teleophthalmology devices have matured into reliable tools that can democratize eye care. Their success depends on robust digital infrastructure, rigorous device and algorithm validation, and sustainable financing models. Investment in local training, community engagement, and interoperable referral networks is crucial for translating technological advances into meaningful reductions in rural vision impairment.</p>","PeriodicalId":94006,"journal":{"name":"Expert review of medical devices","volume":" ","pages":"1167-1172"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145133104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Securing the internet of medical things in remote patient monitoring and the hospital at home: an interview with Stephen Gilbert. 在远程病人监控和家庭医院中保护医疗物联网:对斯蒂芬·吉尔伯特的采访。
IF 2.7 Pub Date : 2025-11-01 Epub Date: 2025-09-25 DOI: 10.1080/17434440.2025.2566746
Stephen Gilbert
{"title":"Securing the internet of medical things in remote patient monitoring and the hospital at home: an interview with Stephen Gilbert.","authors":"Stephen Gilbert","doi":"10.1080/17434440.2025.2566746","DOIUrl":"10.1080/17434440.2025.2566746","url":null,"abstract":"","PeriodicalId":94006,"journal":{"name":"Expert review of medical devices","volume":" ","pages":"1155-1157"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145139814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the effectiveness and safety of a remote electrical neuromodulation wearable device in treating chronic and episodic migraine: a retrospective, observational real-world evidence from India. 评估远程电神经调节可穿戴设备治疗慢性和发作性偏头痛的有效性和安全性:来自印度的回顾性观察性现实证据。
IF 2.7 Pub Date : 2025-11-01 Epub Date: 2025-10-02 DOI: 10.1080/17434440.2025.2566742
Sujeet Narayan Charugulla, Mayank Ravindra Dhore, Alit Stark-Inbar, Bhavesh Prabhudas Kotak, Sukhpreet Singh

Background: The remote electrical neuromodulation (REN) wearable device offers a noninvasive, non-pharmacological option for migraine management, but its role in Indian healthcare remains unexplored.

Research design and methods: This retrospective, observational, real-world analysis included patients prescribed REN (Nerivio®) by neurologists across India. Deidentified data were collected via the Portea Medical patient support program, with a three-month follow-up. The primary outcome assessed the effectiveness and safety of the device. Secondary outcomes included changes in headache frequency and medication regimes.

Results: The study population included 1033 patients (mean [SD] age: 38.8 [13] years; 74.8% female; 84.6% with chronic migraine). At two hours post-treatment with REN, 57.3% reported pain relief, 29.4% achieved pain freedom, 47.1% experienced relief from functional disability, and 26.1% reported complete freedom from functional disability. At three months, 70.3% found REN effective. The mean visual analog scale score for pain severity decreased by 2.3 units (p < 0.001). No adverse events occurred in 38.7% of patients. REN usage significantly reduced monthly headache days, frequency of oral medication use, and medicine dosage.

Conclusion: REN is an effective, safe, and well-tolerated non-pharmacological option for migraine management in India. However, long-term studies are necessary to extend these findings across diverse populations.

Trial registration: ClinicalTrials.gov (CTRI/2024/11/076750).

背景:远程电神经调节(REN)可穿戴设备为偏头痛治疗提供了一种无创、非药物的选择,但其在印度医疗保健中的作用仍未被探索。研究设计和方法:这项回顾性、观察性、现实世界分析包括印度各地神经科医生开REN (Nerivio®)处方的患者。通过波特亚医疗病人支持计划收集未识别的数据,并进行三个月的随访。主要结果评估了该装置的有效性和安全性。次要结局包括头痛频率和用药方案的改变。结果:研究人群包括1033例患者(平均[SD]年龄:38.8岁,74.8%为女性,84.6%为慢性偏头痛)。在REN治疗2小时后,57.3%的患者报告疼痛缓解,29.4%的患者获得疼痛缓解,47.1%的患者功能障碍缓解,26.1%的患者功能障碍完全消除。三个月后,70.3%的人认为REN有效。疼痛严重程度的平均视觉模拟量表评分降低了2.3个单位(p)。结论:REN是印度偏头痛治疗的有效、安全、耐受性良好的非药物选择。然而,要将这些发现扩展到不同的人群,还需要长期的研究。试验注册:ClinicalTrials.gov (CTRI/2024/11/076750)。
{"title":"Evaluating the effectiveness and safety of a remote electrical neuromodulation wearable device in treating chronic and episodic migraine: a retrospective, observational real-world evidence from India.","authors":"Sujeet Narayan Charugulla, Mayank Ravindra Dhore, Alit Stark-Inbar, Bhavesh Prabhudas Kotak, Sukhpreet Singh","doi":"10.1080/17434440.2025.2566742","DOIUrl":"10.1080/17434440.2025.2566742","url":null,"abstract":"<p><strong>Background: </strong>The remote electrical neuromodulation (REN) wearable device offers a noninvasive, non-pharmacological option for migraine management, but its role in Indian healthcare remains unexplored.</p><p><strong>Research design and methods: </strong>This retrospective, observational, real-world analysis included patients prescribed REN (Nerivio®) by neurologists across India. Deidentified data were collected via the Portea Medical patient support program, with a three-month follow-up. The primary outcome assessed the effectiveness and safety of the device. Secondary outcomes included changes in headache frequency and medication regimes.</p><p><strong>Results: </strong>The study population included 1033 patients (mean [SD] age: 38.8 [13] years; 74.8% female; 84.6% with chronic migraine). At two hours post-treatment with REN, 57.3% reported pain relief, 29.4% achieved pain freedom, 47.1% experienced relief from functional disability, and 26.1% reported complete freedom from functional disability. At three months, 70.3% found REN effective. The mean visual analog scale score for pain severity decreased by 2.3 units (<i>p</i> < 0.001). No adverse events occurred in 38.7% of patients. REN usage significantly reduced monthly headache days, frequency of oral medication use, and medicine dosage.</p><p><strong>Conclusion: </strong>REN is an effective, safe, and well-tolerated non-pharmacological option for migraine management in India. However, long-term studies are necessary to extend these findings across diverse populations.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov (CTRI/2024/11/076750).</p>","PeriodicalId":94006,"journal":{"name":"Expert review of medical devices","volume":" ","pages":"1257-1263"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145188139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Visual standardisation of airway devices: can universal colour coding improve outcomes in time-critical settings? 气道设备的视觉标准化:通用颜色编码能否改善时间紧迫情况下的结果?
IF 2.7 Pub Date : 2025-11-01 Epub Date: 2025-09-23 DOI: 10.1080/17434440.2025.2564356
Anju Gupta, Nitin Choudhary
{"title":"Visual standardisation of airway devices: can universal colour coding improve outcomes in time-critical settings?","authors":"Anju Gupta, Nitin Choudhary","doi":"10.1080/17434440.2025.2564356","DOIUrl":"10.1080/17434440.2025.2564356","url":null,"abstract":"","PeriodicalId":94006,"journal":{"name":"Expert review of medical devices","volume":" ","pages":"1159-1161"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145082971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How can we improve patient access to LVAD therapy? 我们如何改善患者获得LVAD治疗的机会?
IF 2.7 Pub Date : 2025-11-01 Epub Date: 2025-09-11 DOI: 10.1080/17434440.2025.2560666
Chonyang Albert, Jagpreet S Grewal, Maya Guglin
{"title":"How can we improve patient access to LVAD therapy?","authors":"Chonyang Albert, Jagpreet S Grewal, Maya Guglin","doi":"10.1080/17434440.2025.2560666","DOIUrl":"10.1080/17434440.2025.2560666","url":null,"abstract":"","PeriodicalId":94006,"journal":{"name":"Expert review of medical devices","volume":" ","pages":"1163-1165"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145031557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Locomotors disability assistive devices for frail persons: An update with focus on advancement in hybrid assistive devices. 为体弱人士设计的运动残疾辅助装置:一种专注于混合辅助装置进步的更新。
IF 2.7 Pub Date : 2025-11-01 Epub Date: 2025-09-13 DOI: 10.1080/17434440.2025.2560660
Rohit Kumar, Janakarajan Ramkumar, Mohan Gurjar, Siddharth Rai

Introduction: The World Health Organization (WHO) reported in 2023 that approximately 1.3 billion people, or 16% of the global population, are living with a disability. Among these, locomotor disabilities constitute a significant portion, underscoring the urgent need for devices that enhance mobility and support daily living. The growing demand for assistive devices highlights the critical importance of tools that foster independence and improve overall health and well-being for individuals with mobility impairments.

Area covered: This review provides an update on the existing locomotor assistive devices (LADs), exploring their applications, benefits, limitations, and areas where further advancements are necessary. Special attention is given to hybrid assistive devices, a recent innovation that integrates mobility aids, transfer systems, and rehabilitation tools into a unified platform.

Expert opinion: The LADs, particularly hybrid devices, not only promote user autonomy but also alleviate the caregiver demands. Additionally, this review also suggests areas for future research and development, focusing on improving the accessibility, usability, and affordability of LADs to enhance the quality of life for individuals with locomotor disabilities.

导言:世界卫生组织(世卫组织)在2023年报告称,约有13亿人患有残疾,占全球人口的16%。其中,运动障碍占很大一部分,强调了对增强行动能力和支持日常生活的设备的迫切需要。对辅助器具日益增长的需求凸显了工具的关键重要性,这些工具可以促进行动障碍患者的独立性并改善其整体健康和福祉。涵盖领域:这篇综述提供了现有运动辅助装置(LADs)的最新进展,探讨了它们的应用、好处、局限性和需要进一步发展的领域。特别关注混合辅助装置,这是最近的一项创新,将移动辅助设备、转移系统和康复工具集成到一个统一的平台中。专家意见:lad,特别是混合设备,不仅提高了用户的自主权,而且减轻了护理人员的需求。此外,本综述还提出了未来研究和发展的领域,重点是提高lad的可及性、可用性和可负担性,以提高运动障碍患者的生活质量。
{"title":"Locomotors disability assistive devices for frail persons: An update with focus on advancement in hybrid assistive devices.","authors":"Rohit Kumar, Janakarajan Ramkumar, Mohan Gurjar, Siddharth Rai","doi":"10.1080/17434440.2025.2560660","DOIUrl":"10.1080/17434440.2025.2560660","url":null,"abstract":"<p><strong>Introduction: </strong>The World Health Organization (WHO) reported in 2023 that approximately 1.3 billion people, or 16% of the global population, are living with a disability. Among these, locomotor disabilities constitute a significant portion, underscoring the urgent need for devices that enhance mobility and support daily living. The growing demand for assistive devices highlights the critical importance of tools that foster independence and improve overall health and well-being for individuals with mobility impairments.</p><p><strong>Area covered: </strong>This review provides an update on the existing locomotor assistive devices (LADs), exploring their applications, benefits, limitations, and areas where further advancements are necessary. Special attention is given to hybrid assistive devices, a recent innovation that integrates mobility aids, transfer systems, and rehabilitation tools into a unified platform.</p><p><strong>Expert opinion: </strong>The LADs, particularly hybrid devices, not only promote user autonomy but also alleviate the caregiver demands. Additionally, this review also suggests areas for future research and development, focusing on improving the accessibility, usability, and affordability of LADs to enhance the quality of life for individuals with locomotor disabilities.</p>","PeriodicalId":94006,"journal":{"name":"Expert review of medical devices","volume":" ","pages":"1215-1229"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Software as Medical Devices: requirements and regulatory landscape in the United States. 作为医疗设备的软件:美国的要求和监管环境。
IF 2.7 Pub Date : 2025-11-01 Epub Date: 2025-10-14 DOI: 10.1080/17434440.2025.2561918
Shivani Shah, Priyanka Thakor, Aakash Shah, Om V Singh

Introduction: The integration of software into medical devices has profoundly transformed the healthcare landscape, enabling precise diagnostics, personalized treatment , and remote patient monitoring. The rapid pace of software development - especially with artificial intelligence (AI) and machine learning (ML) - demands regulatory frameworks to ensure patient safety, effectiveness, and reliability.

Areas covered: Software as a Medical Device (SaMD) refers to software intended for medical purposes that operates independently of a physical device. This article traces the historical development of regulatory approaches, deconstructs existing frameworks, analyzes challenges and influencing factors, presents case studies, and anticipates future trends. A narrative literature search was conducted using PubMed, Google Scholar, FDA.gov, EUR-Lex and IMDRF.org, covering materials published between January 2013 and May 2025.

Expert opinion: The Total Product Lifecycle (TPLC) framework is essential for managing evolving risks and performance of AI/ML-based SaMD. These technologies are redefining regulatory assumptions, requiring systems that ensure transparency, mitigate bias, sustain trust, and promote equitable, safe innovation.

简介:将软件集成到医疗设备中已经深刻地改变了医疗保健领域,实现了更精确的诊断、个性化的治疗计划和远程患者监控。软件开发的快速发展——尤其是人工智能(AI)和机器学习(ML)等新兴技术——需要专门的监管框架来确保患者安全、临床有效性和产品可靠性。涵盖领域:作为医疗设备的软件(SaMD)是指用于医疗目的的独立于物理医疗设备运行的软件。本文追溯了监管方法的历史发展,解构了现有框架,分析了关键挑战和影响因素,提出了案例研究,并预测了未来的趋势。使用PubMed、谷歌Scholar、FDA.gov、EUR-Lex和IMDRF.org进行叙事文献检索,检索时间为2013年1月至2025年5月。专家意见:整个产品生命周期(TPLC)框架对于管理与基于AI/ ml的SaMD相关的不断发展的性能和风险至关重要。人工智能/机器学习驱动的SaMD不仅改变了医疗保健服务,而且正在挑战和重新定义医疗监管的基本假设。监管体系必须不断发展,确保透明度,维护公众信任,解决算法偏见,促进公平获得这些先进技术的好处。创新必须以安全、诚信和公平为基础的框架为指导。
{"title":"Software as Medical Devices: requirements and regulatory landscape in the United States.","authors":"Shivani Shah, Priyanka Thakor, Aakash Shah, Om V Singh","doi":"10.1080/17434440.2025.2561918","DOIUrl":"10.1080/17434440.2025.2561918","url":null,"abstract":"<p><strong>Introduction: </strong>The integration of software into medical devices has profoundly transformed the healthcare landscape, enabling precise diagnostics, personalized treatment , and remote patient monitoring. The rapid pace of software development - especially with artificial intelligence (AI) and machine learning (ML) - demands regulatory frameworks to ensure patient safety, effectiveness, and reliability.</p><p><strong>Areas covered: </strong>Software as a Medical Device (SaMD) refers to software intended for medical purposes that operates independently of a physical device. This article traces the historical development of regulatory approaches, deconstructs existing frameworks, analyzes challenges and influencing factors, presents case studies, and anticipates future trends. A narrative literature search was conducted using PubMed, Google Scholar, FDA.gov, EUR-Lex and IMDRF.org, covering materials published between January 2013 and May 2025.</p><p><strong>Expert opinion: </strong>The Total Product Lifecycle (TPLC) framework is essential for managing evolving risks and performance of AI/ML-based SaMD. These technologies are redefining regulatory assumptions, requiring systems that ensure transparency, mitigate bias, sustain trust, and promote equitable, safe innovation.</p>","PeriodicalId":94006,"journal":{"name":"Expert review of medical devices","volume":" ","pages":"1201-1214"},"PeriodicalIF":2.7,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145066937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Expert review of medical devices
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1